Pharma Strategy Blog

What if outside of a few high-profile areas, the past decade has seen far too few commercial innovations that can transform lives and move the economy forward? What if, rather than being an era of rapid innovation, this has been an era of innovation interrupted?

Note to self: check out the "The Freedom to Cure Cancer" by David Dooling on open source software in the Human Genome Project post meeting!

In a business world created through executive order and maintained through fake federal money, all other players in the market – if they are paying attention – should view future market dynamics with the confusion reserved for a fever dream. It makes competitive intelligence extraordinarily necessary, and partially impossible.

The gist: We have convinced ourselves that we live in revolutionary innovative times, but we have much less to show for it than we should. In a sense, we staffed up for the coming rush of new-new things — took on credit, hired like mad, and spent wildly anticipating growth — only to find that new products took much longer coming than anyone expected. As a result, the binge left us a tottering and insolvent mess. I've often thought that about Pharma megamergers too… the lazy way to growth rather than relying on true innovation.